Cover ImageSALE
市場調查報告書

多發性硬化症的幹細胞療法市場:開發平台分析報告

Stem Cell Therapy for Multiple Sclerosis - A Pipeline Analysis report

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 609180
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
多發性硬化症的幹細胞療法市場:開發平台分析報告 Stem Cell Therapy for Multiple Sclerosis - A Pipeline Analysis report
出版日期: 2018年02月27日 內容資訊: 英文 72 Pages
簡介

本報告提供各種發展階段的分子,多發性硬化症的幹細胞療法的臨床試驗情形的詳細分析。再加上含給藥途徑的各種市場區隔為基礎開發平台分子的治療評估相關資訊。

本報告處理的項目

  • 多發性硬化症的各種發展階段的幹細胞分子
  • 現在從事多發性硬化症的幹細胞治療分子開發的企業
  • 來自恰當推論的中斷/惰性分子的考察
  • 批准藥的主要法規當局:各地區
  • 活性分子詳細的分析

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 多發性硬化症的幹細胞療法:洞察

  • 簡介

第5章 主要法規當局

  • 美國
  • 歐洲
  • 日本
  • 澳洲
  • 中國

第6章 開發平台形勢

第7章 比較分析

  • 中期分子(階段I / II)
  • 初期階段的分子(階段I)
  • 前臨床及發現階段的分子
  • 惰性(狀態未知及終結)分子

第8章 表示分析

第9章 治療評估:各ROA

第10章 主要企業

  • 活躍的企業:範疇與參數

第11章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR20309

This pipeline analysis report offers detailed insights into the clinical trials landscape of the stem cell therapy for multiple sclerosis including molecules at different development stages. Moreover, the report also offers information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration.

Key questions answered in the report include:

  • What are the stem cell molecules in the various development stages for multiple sclerosis?
  • What are the companies that are currently involved in the development of stem cell therapy molecules for multiple sclerosis?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: STEM CELL THERAPY FOR MULTIPLE SCLEROSIS: AN INSIGHT

  • Introduction

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • Japan
  • Australia
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Mid-stage molecules (Phase I/II), 2017
  • Early-stage molecule (Phase I), 2017
  • Pre-clinical and discovery stage molecules, 2017
  • Inactive (status unknown and terminated) molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT BY ROA

PART 10: KEY COMPANIES

  • Active companies: Category and parameters

PART 11: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Drug approval process by US FDA
  • Exhibit 02: Pipeline landscape
  • Exhibit 03: Pipeline molecules in different developmental stages 2017
  • Exhibit 04: Overview: Human umbilical cord mesenchymal stem cells
  • Exhibit 05: Clinical trials description of Huma umbilical cord mesenchymal stem cells
  • Exhibit 06: Overview: Autologous adipose-derived mesenchymal cells
  • Exhibit 07: Clinical trials description of Autologous adipose-derived mesenchymal cells
  • Exhibit 08: Overview: PDA-001
  • Exhibit 09: Clinical trials description of PDA-001
  • Exhibit 10: Overview: MultiStem
  • Exhibit 11: Overview: MSC-NTF
  • Exhibit 12: Overview: AST-OPC1
  • Exhibit 13: Overview: NSI-777
  • Exhibit 14: Overview: ALLOCETRA
  • Exhibit 15: Overview: NeurArrest
  • Exhibit 16: Overview: Adult stem cell therapy
  • Exhibit 17: Overview: Umbilical cord-derived mesenchymal stem cells
  • Exhibit 18: Clinical trials description of Umbilical cord-derived mesenchymal stem cells
  • Exhibit 19: Overview: Autologous bone marrow-derived mononuclear stem cells
  • Exhibit 20: Clinical trials description of Autologous bone marrow-derived mononuclear stem cells
  • Exhibit 21: Pipeline molecules as per types of multiple sclerosis
  • Exhibit 22: Assessment by RoA
  • Exhibit 23: Active companies: Category and parameters 2017
  • Exhibit 24: Segmentation of companies 2017
  • Exhibit 25: Overview: American CryoStem 2017
  • Exhibit 26: Overview: Asterias Biotherapeutics 2017
  • Exhibit 27: Overview: Athersys 2017
  • Exhibit 28: Overview: Brainstorm Cell Therapeutics 2017
  • Exhibit 29: Overview: Celgene Cellular Therapeutics 2017
  • Exhibit 30: Overview: Cell Cure Neurosciences 2017
  • Exhibit 31: Overview: DaVinci Biosciences 2017
  • Exhibit 32: Overview: Enlivex Therapeutics 2017
  • Exhibit 33: Overview: Neuralstem 2017
  • Exhibit 34: Overview: Translational Biosciences 2017
Back to Top